Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Paul G. Richardson, Fredrik Schjesvold, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Paula Rodriguez-Otero, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Meral Beksac, Albert Oriol, Jindriska Lindsay, Anna Marina Liberati, Monica Galli, Pawel RobakAlessandra Larocca, Munci Yagci, Filiz Vural, Abraham S. Kanate, Ruiyun Jiang, Lara Grote, Teresa Peluso, Meletios Dimopoulos

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
Original languageEnglish
Pages (from-to)73-83
Number of pages11
JournalEuropean Journal of Haematology
Volume108
Issue number1
DOIs
Publication statusPublished - Jan 2022
Externally publishedYes

ASJC Scopus Subject Areas

  • Hematology

Keywords

  • aged
  • chromosome aberrations
  • multiple myeloma
  • pomalidomide
  • renal insufficiency

Fingerprint

Dive into the research topics of 'Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics'. Together they form a unique fingerprint.

Cite this